Cite
Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.
MLA
de Rooij, Martin F. M., et al. “Ibrutinib and Idelalisib Synergistically Target BCR-Controlled Adhesion in MCL and CLL: A Rationale for Combination Therapy.” Blood, vol. 125, no. 14, Apr. 2015, pp. 2306–08. EBSCOhost, https://doi.org/10.1182/blood-2014-12-619163.
APA
de Rooij, M. F. M., Kuil, A., Kater, A. P., Kersten, M. J., Pals, S. T., & Spaargaren, M. (2015). Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. Blood, 125(14), 2306–2308. https://doi.org/10.1182/blood-2014-12-619163
Chicago
de Rooij, Martin F. M., Annemieke Kuil, Arnon P. Kater, Marie José Kersten, Steven T. Pals, and Marcel Spaargaren. 2015. “Ibrutinib and Idelalisib Synergistically Target BCR-Controlled Adhesion in MCL and CLL: A Rationale for Combination Therapy.” Blood 125 (14): 2306–8. doi:10.1182/blood-2014-12-619163.